Xencor (NASDAQ:XNCR) Given New $67.00 Price Target at Piper Jaffray Companies

Xencor (NASDAQ:XNCR) had its price objective lifted by Piper Jaffray Companies from $56.00 to $67.00 in a report released on Monday morning, The Fly reports. They currently have an overweight rating on the biopharmaceutical company’s stock.

Other analysts also recently issued research reports about the stock. Cantor Fitzgerald restated a buy rating and set a $40.00 price objective on shares of Xencor in a research report on Sunday, May 12th. Zacks Investment Research downgraded shares of Zynex from a hold rating to a sell rating in a research report on Saturday, May 4th. Raymond James assumed coverage on shares of Gritstone Oncology in a research report on Thursday, March 14th. They issued an outperform rating and a $20.00 price target for the company. ValuEngine downgraded shares of Zumiez from a hold rating to a sell rating in a research report on Tuesday, July 2nd. Finally, BidaskClub upgraded shares of Zynerba Pharmaceuticals from a hold rating to a buy rating in a research report on Thursday, June 20th. Two investment analysts have rated the stock with a sell rating, one has given a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the company. The stock has a consensus rating of Buy and a consensus price target of $43.44.

Shares of NASDAQ:XNCR opened at $43.93 on Monday. The stock has a market cap of $2.50 billion, a P/E ratio of 68.32 and a beta of 1.45. The company has a quick ratio of 6.66, a current ratio of 6.66 and a debt-to-equity ratio of 0.02. Xencor has a twelve month low of $27.75 and a twelve month high of $48.38. The business’s 50 day moving average is $35.81.

Xencor (NASDAQ:XNCR) last issued its quarterly earnings data on Thursday, May 9th. The biopharmaceutical company reported $1.38 earnings per share for the quarter, topping the consensus estimate of $0.43 by $0.95. The company had revenue of $111.94 million for the quarter, compared to analysts’ expectations of $60.05 million. As a group, equities research analysts expect that Xencor will post -0.08 EPS for the current fiscal year.

In other news, major shareholder John S. Stafford III acquired 12,641 shares of the business’s stock in a transaction on Thursday, June 6th. The stock was bought at an average price of $29.87 per share, for a total transaction of $377,586.67. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, major shareholder John S. Stafford III acquired 14,611 shares of the business’s stock in a transaction on Thursday, May 2nd. The shares were purchased at an average price of $29.87 per share, with a total value of $436,430.57. The disclosure for this purchase can be found here. 4.33% of the stock is owned by corporate insiders.

A number of institutional investors have recently made changes to their positions in XNCR. California Public Employees Retirement System raised its position in Xencor by 9.8% during the 4th quarter. California Public Employees Retirement System now owns 51,814 shares of the biopharmaceutical company’s stock worth $1,874,000 after buying an additional 4,616 shares during the last quarter. BlackRock Inc. raised its position in Xencor by 2.5% during the 4th quarter. BlackRock Inc. now owns 4,152,607 shares of the biopharmaceutical company’s stock worth $150,159,000 after buying an additional 100,924 shares during the last quarter. Citigroup Inc. raised its position in Xencor by 301.0% during the 4th quarter. Citigroup Inc. now owns 40,546 shares of the biopharmaceutical company’s stock worth $1,467,000 after buying an additional 30,435 shares during the last quarter. GSA Capital Partners LLP purchased a new position in Xencor during the 4th quarter worth $339,000. Finally, Northern Trust Corp raised its position in Xencor by 0.3% during the 4th quarter. Northern Trust Corp now owns 603,917 shares of the biopharmaceutical company’s stock worth $21,838,000 after buying an additional 1,751 shares during the last quarter. Institutional investors own 83.51% of the company’s stock.

About Xencor

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and other protein therapeutics to treat severe and life threatening diseases with unmet medical needs. It develops its antibody product candidates to treat autoimmune and allergic diseases, cancer, and other conditions.

See Also: Find a Trading Strategy That Works

The Fly

Analyst Recommendations for Xencor (NASDAQ:XNCR)

Receive News & Ratings for Xencor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor and related companies with MarketBeat.com's FREE daily email newsletter.